The series A funding will help UMass-founded genetic disease therapy developer Apic Bio progress targeted drugs for ALS and Alpha-1 antitrypsin deficiency.

Apic Bio, a US-based genetic disease therapeutics spinout of University of Massachusetts Medical School (UMMS), closed a $40m series A round on Monday led by Morningside Venture Capital, the VC arm of investment firm Morningside Group. The round included Alpha-1 Project, a profit-led subsidiary of Alpha-1 Foundation, as well as the ALS Investment Fund and…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.